Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England
Andrea Kuhnl, et al.
In this study, 122 patients were treated with axicabtagene ciloleucel and tisagenlecleucel. Details on bridging therapy, treatment-related toxicities and outcomes will be provided at the meeting, by which time 62 patients will have completed their 3 months PET response assessment
